IL284700B2 - Treating eye conditions with angiopoietin-like 7 inhibitors - Google Patents

Treating eye conditions with angiopoietin-like 7 inhibitors

Info

Publication number
IL284700B2
IL284700B2 IL284700A IL28470021A IL284700B2 IL 284700 B2 IL284700 B2 IL 284700B2 IL 284700 A IL284700 A IL 284700A IL 28470021 A IL28470021 A IL 28470021A IL 284700 B2 IL284700 B2 IL 284700B2
Authority
IL
Israel
Prior art keywords
angptl7
seq
nucleic acid
position corresponding
acid molecule
Prior art date
Application number
IL284700A
Other languages
English (en)
Hebrew (he)
Other versions
IL284700B1 (en
IL284700A (en
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL284700A publication Critical patent/IL284700A/en
Publication of IL284700B1 publication Critical patent/IL284700B1/en
Publication of IL284700B2 publication Critical patent/IL284700B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL284700A 2019-01-23 2020-01-21 Treating eye conditions with angiopoietin-like 7 inhibitors IL284700B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962795665P 2019-01-23 2019-01-23
US201962880609P 2019-07-30 2019-07-30
US201962902683P 2019-09-19 2019-09-19
US201962909573P 2019-10-02 2019-10-02
PCT/US2020/014373 WO2020154268A2 (en) 2019-01-23 2020-01-21 Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors

Publications (3)

Publication Number Publication Date
IL284700A IL284700A (en) 2021-08-31
IL284700B1 IL284700B1 (en) 2025-06-01
IL284700B2 true IL284700B2 (en) 2025-10-01

Family

ID=69591771

Family Applications (1)

Application Number Title Priority Date Filing Date
IL284700A IL284700B2 (en) 2019-01-23 2020-01-21 Treating eye conditions with angiopoietin-like 7 inhibitors

Country Status (11)

Country Link
US (2) US11767526B2 (enExample)
EP (1) EP3914711A2 (enExample)
JP (2) JP2022523301A (enExample)
KR (1) KR20210132045A (enExample)
CN (1) CN113646432A (enExample)
AU (1) AU2020210630B2 (enExample)
CA (1) CA3126476A1 (enExample)
IL (1) IL284700B2 (enExample)
MX (1) MX2021008797A (enExample)
SG (1) SG11202107497XA (enExample)
WO (1) WO2020154268A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11845989B2 (en) 2019-01-23 2023-12-19 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
EP3914711A2 (en) 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
KR20220024153A (ko) 2019-05-24 2022-03-03 엠피리코 인크. 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
EP4221719A4 (en) * 2020-09-29 2025-10-08 Empirico Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN 7 (ANGPTL7) RELATED DISEASES
EP4251753A4 (en) * 2020-11-24 2025-08-06 Empirico Inc TREATMENT OF DISEASES AND DISORDERS RELATED TO SOS2
MX2023009987A (es) * 2021-02-26 2023-09-06 Regeneron Pharma Tratamiento de la inflamacion con glucocorticoides e inhibidores de angiopoyetina tipo 7 (angptl7).
IL311711A (en) * 2021-09-30 2024-05-01 Regeneron Pharma Treatment of lightning using Ru-12 guanine nucleotide exchange factor inhibitors
IL313191A (en) * 2021-12-22 2024-07-01 Regeneron Pharma Treatment of kidney diseases using angiopoietin-like inhibitors 3

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187607A1 (en) * 2012-12-30 2014-07-03 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2015132303A1 (en) * 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
US20180237771A1 (en) * 2016-08-19 2018-08-23 Toolgen Incorporated Artificially-Manipulated Neovascularization Regulatory System

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2292757A3 (en) 2004-08-23 2011-11-16 Sylentis S.A.U. Treatment of eye disorders characterized by an elevated intraocular pressure by siRNAs
US20100028875A1 (en) 2006-07-05 2010-02-04 Mun-Gan Rhyu Method for diagnosing cancer by detecting the methylation of transitional zones
EP2429511B1 (en) 2009-05-11 2019-02-20 Berg LLC Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
HRP20160916T1 (hr) 2009-07-27 2016-11-18 Baxalta GmbH Konjugati proteina za koagulaciju krvi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
CN104530182A (zh) 2009-07-27 2015-04-22 利普森技术有限公司 非凝血蛋白的糖基多唾液酸化
US9795683B2 (en) 2009-07-27 2017-10-24 Lipoxen Technologies Limited Glycopolysialylation of non-blood coagulation proteins
US20130022983A1 (en) 2009-10-26 2013-01-24 Externautics S.P.A. Colon and Rectal Tumor Markers and Methods of Use Thereof
SG181806A1 (en) 2010-01-11 2012-07-30 Genomic Health Inc Method to use gene expression to determine likelihood of clinical outcome of renal cancer
EP2397559A1 (en) 2010-06-17 2011-12-21 Max-Delbrück-Centrum Für Molekulare Medizin Stage-specific biomarkers for the diagnosis of acute kidney injury
WO2012006589A2 (en) 2010-07-08 2012-01-12 Infinity Pharmaceuticals, Inc. Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
ES2731626T3 (es) 2010-07-30 2019-11-18 Baxalta Inc Catalizadores nucleofílicos para enlace oxima
SG191298A1 (en) 2010-12-22 2013-07-31 Baxter Int Materials and methods for conjugating a water soluble fatty acid derivative to a protein
CA2836103C (en) 2011-05-18 2020-07-14 Baxter International Inc. Modification-dependent activity assays
WO2013063510A1 (en) 2011-10-28 2013-05-02 Integritybio Inc. Protein formulations containing amino acids
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
AU2013204754C1 (en) 2012-05-16 2018-10-11 Takeda Pharmaceutical Company Limited Nucleophilic Catalysts for Oxime Linkage
US20130310546A1 (en) 2012-05-16 2013-11-21 Bater Healthcare Sa Nucleophilic catalysts for oxime linkage and use of nmr analyses of the same
WO2013181438A2 (en) 2012-05-30 2013-12-05 Icahn School Of Medicine At Mount Sinai Compositions and methods for modulating pro-inflammatory immune response
US20150299798A1 (en) 2012-09-21 2015-10-22 Integragen Method for classification of liver samples and diagnosis of focal nodule dysplasia, hepatocellular adenoma, and hepatocellular carcinoma
WO2014167529A1 (en) 2013-04-10 2014-10-16 Institut De Cardiologie De Montreal Methods and compositions for preventing and treating atherosclerosis
EP3146041B1 (en) 2014-05-22 2019-03-27 Fred Hutchinson Cancer Research Center Lilrb2 and notch-mediated expansion of hematopoietic precursor cells
CA3005989C (en) 2015-11-24 2025-11-18 University Of Georgia Research Foundation, Inc. VIRUS PRODUCTION IN A CELL CULTURE
KR20180079448A (ko) 2015-11-24 2018-07-10 커먼웰쓰 사이언티픽 앤드 인더스트리얼 리서치 오가니제이션 조류 난에서의 바이러스 생산
EP3436049B1 (en) 2016-03-31 2022-01-12 Baylor Research Institute Angiopoietin-like protein 8 (angptl8)
JP7173962B2 (ja) * 2016-08-30 2022-11-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド グルカゴン受容体シグナル伝達の干渉による重度のインスリン抵抗性の処置方法
WO2018067991A1 (en) 2016-10-07 2018-04-12 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
AU2017357072A1 (en) 2016-11-14 2019-05-30 Memorial Sloan-Kettering Cancer Center Stem cell derived schwann cells
WO2018174861A1 (en) 2017-03-21 2018-09-27 Mprobe Inc. Methods and compositions for detecting early stage breast cancer with rna-seq expression profiling
WO2018175630A1 (en) 2017-03-23 2018-09-27 The Regents Of The University Of California Stimulation of hair growth by senescent cells and senescence associated secretory phenotype
JP2018164442A (ja) * 2017-03-28 2018-10-25 国立大学法人 熊本大学 皮膚有棘細胞癌の判定、予防又は治療方法
JP6779164B2 (ja) * 2017-03-28 2020-11-04 ヤンマーパワーテクノロジー株式会社 作業車両の自律走行システム
JP7493940B2 (ja) 2017-05-31 2024-06-03 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガナイゼーション 鳥類における形質選択
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20210122819A1 (en) 2018-01-18 2021-04-29 Adanate, Inc. Anti-lilrb antibodies and uses thereof
GB201806118D0 (en) 2018-04-13 2018-05-30 Univ Edinburgh Macrophage use
EP3914711A2 (en) 2019-01-23 2021-12-01 Regeneron Pharmaceuticals, Inc. Treatment of ophthalmic conditions with angiopoietin-like 7 (angptl7) inhibitors
KR20220024153A (ko) 2019-05-24 2022-03-03 엠피리코 인크. 안지오포이에틴 유사 7(angptl7) 관련 질환의 치료
EP4221719A4 (en) 2020-09-29 2025-10-08 Empirico Inc COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANGIOPOIETIN 7 (ANGPTL7) RELATED DISEASES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140187607A1 (en) * 2012-12-30 2014-07-03 The Regents Of The University Of California Methods of modulating compliance of the trabecular meshwork
WO2015132303A1 (en) * 2014-03-04 2015-09-11 Sylentis Sau Sirnas and their use in methods and compositions for the treatment and/or prevention of eye conditions
US20180237771A1 (en) * 2016-08-19 2018-08-23 Toolgen Incorporated Artificially-Manipulated Neovascularization Regulatory System

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
. JARU-AMPORNPAN ET AL,, SCREENING ANGIOPOIETIN-LIKE 7 IN PRIMARY CONGENITAL GLAUCOMA PATIENTS - ARVO ANNUAL MEETING ABSTRACT, 31 December 2010 (2010-12-31) *
CHRISTOPHER DEBOEVER ET AL,, BAYESIAN MODEL COMPARISON FOR RARE VARIANT ASSOCIATION STUDIES OF MULTIPLE PHENOTYPES, 14 April 2018 (2018-04-14) *
COLIN E. WILLOUGHBY ET AL,, MUTATIONAL SCREENING OF THE ANGIOPOIETIN-LIKE 7 GENE IN HIGH-TENSION PRIMARY OPEN ANGLE GLAUCOMA. - ARVO ANNUAL MEETING ABSTRACT, 31 December 2012 (2012-12-31) *
JOHN G DOENCH ET AL,, OPTIMIZED SGRNA DESIGN TO MAXIMIZE ACTIVITY AND MINIMIZE OFF-TARGET EFFECTS OF CRISPR-CAS9, 18 January 2016 (2016-01-18) *
KUCHTEY JOHN ET AL,, ANGIOPOIETIN-LIKE 7 SECRETION IS INDUCED BY GLAUCOMA STIMULI AND ITS CONCENTRATION IS ELEVATED IN GLAUCOMATOUS AQUEOUS HUMOR, 31 December 2008 (2008-12-31) *
LAKISHA K. BUIE ET AL,, ANGIOPOIETIN-LIKE 7 (ANGPTL7) MODULATES DEX INDUCTION AND FIBRONECTIN (FN1) FIBRILS FORMATION IN THE HUMAN TRABECULAR MESHWORK (HTM) - ARVO ANNUAL MEETING ABSTRACT, 31 December 2011 (2011-12-31) *
N?RIA COMES ET AL,, EVIDENCE FOR A ROLE OF ANGIOPOIETIN-LIKE 7 (ANGPTL7) IN EXTRACELLULAR MATRIX FORMATION OF THE HUMAN TRABECULAR MESHWORK: IMPLICATIONS FOR GLAUCOMA : ANGPTL7 IN THE HUMAN TRABECULAR MESHWORK, 30 December 2010 (2010-12-30) *
ROZSA F W ET AL,, GENE EXPRESSION PROFILE OF HUMAN TRABECULAR MESHWORK CELLS IN RESPONSE TO LONG-TERM DEXAMETHASONE EXPOSURE, 27 February 2006 (2006-02-27) *
TERESA BORRS,, GENE THERAPY STRATEGIES IN GLAUCOMA AND APPLICATION FOR STEROID-INDUCED HYPERTENSION, 5 August 2011 (2011-08-05) *
YIREN XIAO ET AL,, LOSS OF ANGIOPOIETIN-LIKE 7 DIMINISHES THE REGENERATION CAPACITY OF HEMATOPOIETIC STEM AND PROGENITOR CELLS, 6 February 2015 (2015-02-06) *

Also Published As

Publication number Publication date
KR20210132045A (ko) 2021-11-03
CA3126476A1 (en) 2020-07-30
JP2022523301A (ja) 2022-04-22
US20210277391A1 (en) 2021-09-09
US11767526B2 (en) 2023-09-26
IL284700B1 (en) 2025-06-01
JP2025023307A (ja) 2025-02-14
CN113646432A (zh) 2021-11-12
SG11202107497XA (en) 2021-08-30
EP3914711A2 (en) 2021-12-01
AU2020210630A1 (en) 2021-08-05
AU2020210630B2 (en) 2025-10-23
MX2021008797A (es) 2022-01-31
WO2020154268A3 (en) 2020-09-24
US11512309B2 (en) 2022-11-29
WO2020154268A9 (en) 2021-09-16
US20200231965A1 (en) 2020-07-23
WO2020154268A2 (en) 2020-07-30
IL284700A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US11512309B2 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
US20240102013A1 (en) Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) Inhibitors
US20220089664A1 (en) Treatment Of Ophthalmic Conditions With Angiopoietin-Like 7 (ANGPTL7) Inhibitors
US20250250631A1 (en) Kelch Domain Containing 7B (KLHDC7B) Variants And Uses Thereof
US11845989B2 (en) Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors
RU2812912C2 (ru) Лечение офтальмологических патологических состояний ингибиторами ангиопоэтин-подобного белка 7 (angptl7)
US20230099109A1 (en) Treatment Of Glaucoma With Rho Guanine Nucleotide Exchange Factor 12 (ARHGEF12) Inhibitors
US11865134B2 (en) Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitors
CN116997653A (zh) 用糖皮质激素和血管生成素样7(angptl7)抑制剂治疗炎症
WO2025080823A1 (en) Treatment of macular degeneration with complement factor d (cfd) inhibitors
EP4416286A1 (en) Treatment of uveitis with endoplasmic reticulum aminopeptidase 1 (erap1) inhibitors
US20230023182A1 (en) Methods Of Treating Asthma With Solute Carrier Family 27 Member 3 (SLC27A3) Inhibitors